Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications

Interferons α and β in cancer: therapeutic opportunities from new insights

(2019) Ernest C. Borden   NATURE REVIEWS DRUG DISCOVERY

Radiotherapy in Combination With Cytokine Treatment

(2019) Ondrej Palata et al.   Frontiers in Oncology

Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab

(2019) M. Christina Cox et al.   CLINICAL CANCER RESEARCH

Interferon Signaling is Diminished with Age and is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer

(2019) Jaclyn Sceneay et al.   Cancer Discovery

In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?

(2019) Luciano Castiello et al.   Frontiers in Immunology

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

(2018) Michael B. Atkins et al.   CLINICAL CANCER RESEARCH

The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer

(2018) Mary R. Doherty et al.   DNA AND CELL BIOLOGY

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments

(2018) Kevin C. Barry et al.   NATURE MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells

(2018) Luciano Castiello et al.   Cancer Immunology Research

Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells

(2018) Minmin Liu et al.   CANCER RESEARCH

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

(2018) Diwakar Davar et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review

(2017) Kun Chen et al.   JOURNAL OF AUTOIMMUNITY

Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a–LCOR axis

(2017) Toni Celià-Terrassa et al.   NATURE CELL BIOLOGY

DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats

(2017) David Brocks et al.   NATURE GENETICS

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer

(2017) Mary R. Doherty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden

(2017) Meredith L. Stone et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Type I Interferon in Chronic Virus Infection and Cancer

(2017) Laura M. Snell et al.   TRENDS IN IMMUNOLOGY

Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells

(2017) Alessandra Fragale et al.   Cancer Immunology Research

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

(2017) Anje Cauwels et al.   OncoImmunology

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy

(2016) Xiaohong Wang et al.   CANCER RESEARCH

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients

(2016) Caterina Lapenta et al.   JOURNAL OF IMMUNOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer

(2016) Maria Buoncervello et al.   Oncotarget

Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression

(2016) Yuliya V. Katlinskaya et al.   Cell Reports

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Role of type I interferon in inducing a protective immune response: Perspectives for clinical applications

(2015) Paola Rizza et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Toxicities of Immunotherapy for the Practitioner

(2015) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma

(2015) Carmela Rozera et al.   Journal of Translational Medicine

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response

(2015) Roberto Latagliata et al.   LEUKEMIA & LYMPHOMA

Drug repurposing in oncology—patient and health systems opportunities

(2015) Francesco Bertolini et al.   Nature Reviews Clinical Oncology

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

(2014) T. Bald et al.   Cancer Discovery

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

(2012) M Talpaz et al.   LEUKEMIA

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

(2012) Bradley N Bidwell et al.   NATURE MEDICINE

IFN-  enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing

(2011) F. Spadaro et al.   BLOOD

The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity

(2011) B. C. Burnette et al.   CANCER RESEARCH

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

(2011) Mark S. Diamond et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Interferon-α-Conditioned Human Monocytes Combine a Th1-Orienting Attitude with the Induction of Autologous Th17 Responses: Role of IL-23 and IL-12

(2011) Stefano M. Santini et al.   PLoS One

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

(2010) G. Schiavoni et al.   CANCER RESEARCH

Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial

(2009) María E. Miquilena-Colina et al.   VACCINE